Market report: FTSE falters as US Federal Reserve decision takes centre stage

The FTSE 100 mixed this Wednesday after the (OECD) said the global economy is set to shrink 4.5% in 2020, which is not as bad as the 6% collapse it had forecast in June. Also today - the UK’s inflation fell to 0.2% in August, from 1% in July - due largely to the ‘Eat out to help out’ government scheme. That’s good news for consumers and borrowers, not so great for savers though.

The Hut Group (LON:THG) is one of the biggest gainers after announcing the UK’s largest initial public offering since 2013 netting the company £920m. British homebuilder Redrow (LON:RDW) reported a dive in annual profit, while promising to renew dividend payouts next year.

Construction firm Galliford Try Holdings (LON:GFRD) rose after saying it expects to return to profitability in 2021.

Among the small caps - Shield Therapeutics PLC (LON:STX) swung strongly into profit in its first half following a US$11.4mln upfront payment from ASK Pharm, its partner in China.

Futura Medical PLC (LON:FUM) has said it is “actively engaged” in commercial discussions about its erectile dysfunction (ED) gel ahead of a key meeting with US regulators.

Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) has promised to 'unlock value of StemPrintER asset by listing Accustem Sciences before year end’. All three of these these interviews can be found on our website https://www.proactiveinvestors.co.uk/

Quick facts: THG PLC

Price: 708 GBX

Market: LSE
Market Cap: £6.87 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Bionomics' positive pharmacokinetic results confirms it can begin second...

Bionomics Limited (ASX:BNO) (OTCQB:BNOEF) Executive Chairman Errol De Souza tells Proactive tells Proactive the Adelaide, Australia- based biopharmaceutical company has received positive pharmacokinetic results from a 7-day dosing study to treat PTSD, using its new formulation of BNC210. De...

1 day, 14 hours ago

2 min read